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Abstract 
Diabetes mellitus is associated with several abnormalities of platelet function. Recent studies have
shown that the blood level of platelet activating factor (PAF), a potent inducer of platelet aggregation,
is elevated in insulin dependent diabetes mellitus (IDDM) and remains unchanged in non-insulin
dependent diabetes mellitus (NIDDM) patients. However, the mechanism of this increase in PAF levels
has not been determined. In this study we have measured the activity of plasma PAF acetyihydrolase
(an enzyme that regulates PAF levels) and lipoprotein levels in control subjects and diabetic patients.
The data presented show that plasma PAF acetyihydrolase activity is significantly decreased in IDDM
and is not altered in NIDDM patients. The lipoprotein levels were similar in control and diabetic
subjects and there was no correlation between lipoprotein levels and PAF acetylhydrolase activity.
These results suggest that the elevated levels of PAF in IDDM patients could be due to a decrease in
plasma PAF acetyihydrolase activity (JPMA 45:122,1995).
Introduction 
Patients with diabetes mellitus are known to have an increased risk for coronaiy heart disease and other
vascular disorders1,2. Patients with poorly controlled diabetes usually have several abnormalities of
lipid and lipoprotein metabolism3,4. Increased peroxidation of low density lipoproteins (LDL) leading
to foam cell formation, fatty streaks and plaque formation in the arterial wall is considered as the main
mechanism in the pathogenesis of atherosclerosis5. Another majorcontributing factor in this process is
the hyper-reactivity of platelets which can lead to increased platelet adhesion and aggregation6. Platelet
activating factor (PAF) is a phospholipid which is formed by platelets, leukocytes, mast cells and
vascular endothelial cells in response to several chemical and immune stimuli7. PAF has a wide
spectrum of biological actions which include enhanced platelet aggregation, activation o(mononuclear
cells, increased vascular permeability, hypotension, contraction of smooth muscles and alterations in
the intermediary metabolism7. The biological functions of PAF are regulated by PAF acetylhydrolase
which cleaves PAF to lyso-PAF (inactive product) by hydrolyzing its acetyl moiety7. PAF
acetylhydrolase is associated with both high and low density lipoproteins and it is suggested that the
enzyme activity may correlate with lipoproteins levels8. Recent studies have shown that the blood
levels of PAF are elevated in insulin dependent diabetes mellitus (IDDM) and remain unchanged in
non-insulin dependent diabetes mellitus (NIDDM) patients9. However, it is not known whether this
alteration in IDDM patients is due to an increase in the synthesis or a decrease in the degradation of
PAF. Therefore, in this study we have measured the activity of PAF acetylhydrolase enzyme in plasma
obtained from control, 1DDM and NIDDM patients. We have also measured serum lipoprotein levels
and have looked at their correlation with PAF acetylhydrolase activity in control and diabetic subjects.
Subjects and Methods 
Subjects
Age and sex matched diabetic patients and control subjects were recruited from the Diabetic and
Executive Clinics of the Aga Khan University Hospital, Karachi. The diabetic patients who had
impaired renal function or albuminuria, clinical evidence of cardiovascular disease or on concurrent
medication with aspirin or non-steroidal anti-inflaniniatoty drugs were excluded from the study. An
informed consent was taken from all patients and control subjects before withdrawing the blood for the
study. Venous blood was obtained from all subjects after an overnight fast for the measurement of
serum glucose and lipid profile. Glucose levels were measured by using a glucose analyzer whereas
serum triglycerides, total cholesterol, LDL and HDL levels were determined by standard enzymatic
procedures as described earlier10,11.
PAF Acetylhydrolase Activity
PAF acetyihydrolase activity was measured by the method of Blank et al12. Briefly, blood samples were
mixed with 3.8 (w/v) sodium citrate solution (9:1) and centrifuged at 1,200 g for 20 minutes and
plasma was separated. The enzyme activity was assayed by incubating 150 ul of plasma with unlabeled
PAF (100 uM), 0.1 uCi [3H] PAF (specific activity 110 Ci/mmol) in Tris-HC1 (30 mM, pH 7.4) at
37°C for 15 minutes in a shaking water bath. Each incubation was carried out in duplicate. After 15
minutes the reaction was stopped by adding 0.4 ml of 1 M citric acid. The lipids were extracted by
addition of chloroform methanol (2:1 v/v) and dried under nitrogen. The dried samples were
reconstituted in chloroform and applied to silica gel G thin layer chromatography plates. The plates
were developed in a solvent system containing chloroform: methanol: acetic acid: water(100:60: 16:8
v/v) to a distance of 17 cm. The radioactive zones were located and quantified by the use of a Berthold
TLC linear analyzer and chromatography data system çModel LB 511, Berthold, Germany) as
described earlier13 . The level of significance between control and patient population was calculated by
using the student’s t-test. P values less than 0.05 were considered statistically significant.
Results 
The data presented in Table show the metabolic profile of normal subjects and diabetic patients. As
anticipated, fasting blood glucose levels (mg/dl, mean±SEM; n=8) were higher (p<0.0 1) in patients
with IDDM (294±24) and NIDDM (268±40) as compared control group (100±04). The serum
triglyceride levels were increased by 42% inNIDDM patients (controls 117±7 v/s NIDDM 167±15; p
Figure 1 represents atypical radiochromatographic scan obtained after thin layer chmmatography of the
products of the reaction for PAF acetylhydrolase activity. It shows a marked decrease in the formation
of lyso-PAF (product of PAF degradation) in IDDM patients, whereas no similar change was detected
in NIDDM patients.
Figure 2 presents the data on plasma PAF acetyihydrolase activity which is calculated on the basis of
radioactivity incorporated into the peak of lyso-PAF formed. There was a 35% decrease in the activity
of PAF acetylhydrolase in the plasma of IDDM patients when compared to control subjects (p 
Discussion 
Platelet activating factors has several physiological functions and also acts as a pathological mediator
in allergy, inflammation, asthma and vascular disorders7,8. Recent studies have shown that the serum
levels of PAF are elevated in IDDM patients9. The increase in PAF levels could be due to increased
biosynthesis or decreased degradation of PAF. The data presented in this study demonstrate that there is
a decrease in the activity of PAP acetyihydrolase in patients with IDDM. A decrease in the PAP
acetylhydrolase activity would indicate that the degradation of PAF would be slowed leading to an
increase in the serum levels of PAP resulting in an enhancement of its effects. This is supported by the
reports that diabetic human platelets show hypersensitivity to PAP in both aggregation as well as in
phosphatidic acid production14. The plasma PAF acetyihydrolase has recently been shown to prevent
oxidative modification of LDL15. A decrease in its activity may enhance oxidation of LDL and promote
atherogenesis. Plasma PAP acetylhydrolase is associated with lipoprotein fractions and it s activity may
correlate with LDL levels8. In our study the levels of total cholesterol, HDL and LDL were similar
among control and diabetic subjects and there was no correlation between lipoprotein levels and PAP
acetyihydrolase activity. Our results indicate that an alteration in the lipoprotein metabolism is not
necessarily required for a change in PAP acetylhydrolase activity. This is further supported by the work
of Satoh et al16 who have shown that PAF acetylhydrolase activity is increased in patients with
essential hypertension who have normal plasma lipoprotein levels. Thus, inadditiontolipoproteins, other
factors may also be involved in the regulation of PAP acetyihydrolase activity. A decrease in PAP
acetylhydrolase activity in IDDM patients will eventually result in enhanced effects of PAF. This in
turn can influence the actions of PAP in diabetes. PAF has been shownto induce hepatic
glycogenolysis17. Anincrease in PAF levels in diabetics can aggravate hyperglycemia. PAF also
increases hepatic fatty acid and triglyceride synthesis18 and thus it may be partly responsible for the
hypertriglyceridemia seen in diabetic patients. Finally, the increased responsiveness of platelets of
diabetic patients to various aggregating agents including PAP may be responsible for the increased
incidence of vascular complications which are commonly found in diabetes6.
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